Nine-valent refers to the nine-valent human papillomavirus vaccine, which you can’t get over the age of 26. Nine-valent human papillomavirus vaccine can prevent cervical cancer and precancerous lesions caused by HPV types. The target of the vaccination is for women aged 16 to 26 years old. Usually, after the cervical cancer vaccination, the body can be induced to produce corresponding antibodies, thus playing a role in preventing the disease. The vaccine has not yet been shown to be effective in preventing disease in people already infected with the HPV types contained in the vaccine. The risk of exposure to HPV increases with age, especially with the onset of sexual activity, so the benefit of vaccination increases in the younger age groups in the 16-26 age range. In addition, the vaccine is not a substitute for routine cervical cancer screening, nor is it a substitute for other measures to prevent HPV infection and sexually transmitted diseases. Therefore, routine cervical cancer screening remains extremely important.